Organon's VTAMA Shows Early Sleep Benefits in Young Atopic Dermatitis Patients
Event summary
- Organon presented sub-analysis data at AAAAI 2026 showing VTAMA cream improved sleep outcomes in pediatric atopic dermatitis patients as young as 2 years old.
- POEM and DFI sleep subdomain scores showed significant improvements by week 1 or 2 across all age groups studied (2-17 years).
- VTAMA was FDA-approved for atopic dermatitis in December 2024, with prior approval for plaque psoriasis in May 2022.
- The analysis pooled data from 654 children in the ADORING 1 and ADORING 2 Phase 3 trials.
The big picture
Organon's data highlights the growing focus on patient-reported outcomes in dermatology, particularly sleep disruption - a critical but often under-addressed aspect of atopic dermatitis. The findings position VTAMA as a potential leader in pediatric formulations, where treatment options remain limited. This strategic advantage comes as Organon seeks to expand its dermatology portfolio beyond its established psoriasis indication.
What we're watching
- Market Positioning
- How Organon will leverage these pediatric sleep data points to differentiate VTAMA in the competitive atopic dermatitis market.
- Regulatory Strategy
- Whether this sub-analysis could support potential label expansions or new indications for VTAMA.
- Commercialization Pace
- The speed with which Organon can translate these findings into prescribing patterns among pediatric dermatologists.
Related topics